Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs at FEMASYS INC (FEMY), bought 3,125 shares at $3.20 ($10K) on 2026-08-07, disclosed to the SEC on 2026-08-11.
Chief Clinical-Medical Affairs Jeffrey Mifek purchased 3,125 shares for $10,000 at $3.20, marking the largest insider purchase in the company's history. This move comes as the stock has crashed nearly 68% over the last 90 days, potentially signaling a contrarian bet on the oversold equity.
FEMY has suffered a severe drawdown, dropping 68.31% over the last 90 days and 37.53% in the past 30 days. The stock is currently trading at $2.455, which is 80.38% below its 52-week high of $12.51.
1) Next earnings date: Q3 earnings on 2026-11-05 (based on earnings.next_earnings_date). 2) Product expansion: Femasys announced a partnership with Medical Electronic Systems on 2025-09-23 to expand its infertility portfolio with the FemSperm Analysis Kit. 3) Insider momentum: This is the largest insider purchase ever recorded for FEMY, with a pit cluster size of 2.
1) Dilution risk: The company recently priced an $8 million public offering on 2025-08-26, which contributed to a 27% stock drop on 2025-08-27. 2) Short interest: The stock has a short interest of 9.19% of the float, indicating significant bearish sentiment.
Something here stands out, but not much.